Search

Displaying results 2191 - 2200 of 9705 in total
  1. Drug

    CSIC002

    go.drugbank.com/drugs/DB18584
    Experimental

    CSIC002 is a small-molecule Sema-3A inhibitor. It is being investigated for the treatment of anterior ischemic optic neuropathy.

  2. Drug

    LY-2881835

    go.drugbank.com/drugs/DB15046
    Investigational

    LY-2881835 is under investigation in clinical trial NCT01358981 (A Study of LY2881835 in Healthy People and People With Diabetes).

  3. Drug

    AK106-001616

    go.drugbank.com/drugs/DB16058
    Investigational

    AK106-001616 is under investigation in clinical trial NCT01285752 (A Study of AK106-001616 in Patients With Rheumatoid Arthritis (RA)).

  4. Drug

    LY-3200882

    go.drugbank.com/drugs/DB16064
    Investigational

    LY-3200882 is under investigation in clinical trial NCT04158700 (A Study of LY3200882 and Pembrolizumab in Participants With Advanced Cancer).

  5. Drug

    Lisavanbulin

    go.drugbank.com/drugs/DB15224
    Investigational

    Lisavanbulin is under investigation in clinical trial NCT02895360 (Phase 1/2a Study of BAL101553 as 48-hour Infusions in Patients With Advanced Solid Tumors or Recurrent Glioblastoma).

  6. Drug

    Giripladib

    go.drugbank.com/drugs/DB15426
    Investigational

    Giripladib is under investigation in clinical trial NCT00396955 (A Study Comparing 4 Dose Regimens of PLA-695, Naproxen, and Placebo In Subjects With Osteoarthritis Of The Knee).

  7. Drug

    Trilaciclib

    go.drugbank.com/drugs/DB15442
    ApprovedInvestigational

    Trilaciclib, or G1T28, is a CDK4 and CDK6 inhibitor, indicated to reduce the incidence of chemotherapy induced myelosuppression in patients before topotecan-containing or platinum and etoposide-containing

  8. Drug

    Segesterone acetate

    go.drugbank.com/drugs/DB14583
    Approved

    Segesterone acetate is a steroidal progestin or synthetic progesterone and a 19-norprogesterone derivative with no CH3 group radical in position 6 [A37048]. … In clinical trials, Annovera™ achieved a 97.3% success in pregnancy prevention [L4246]. Annovera™ is administered as a vaginal ring that is in place for 21 days and removed for 7 days each cycle.

  9. Drug

    Licofelone

    go.drugbank.com/drugs/DB04725
    Experimental

    It is currently under evaluation as a treatment for osteoarthritis (OA), the most common form of arthritis. … Although phase III trials have been successfully completed in OA patients no dates for regulatory submission have yet been given.

  10. Drug

    Ramoplanin

    go.drugbank.com/drugs/DB04952
    Experimental

    Ramoplanin is a novel glycolipodepsipeptide antibiotic under development for the treatment of CDAD.